Indian firms said that the Bangladeshi company with which Mantralaya is in talks has neither the import licence, nor a manufacturing licenc...

In late May, BDR had sought the approval of India’s drug regulator to make and sell remdesivir in India without entering into an arrangemen...

Use of remdesivir is said to reduce hospital stay by 31 per cent to 11 days from 15 days.

This week, Cipla, Jubilant Life Sciences, Hetero and Mylan signed non-exclusive licensing agreements for the antiviral drug which received ...

Gilead has claimed existing public knowledge as its own and its patent on sofosbuvir, the base compound in its HepC drug Sovaldi, is "unmer...

Natco Pharma has received approval from the Drugs Controller General of India (DCGI) to launch generic version of hepatitis C treatment dru...

Natco Pharma and its partner Alvogen today said they have settled patent infringement suit with Gilead Sciences Inc and others over Tamiflu.

Gilead said that it has also updated the pricing structure for drugs that it will be selling through its partner.

Sofosbuvir is a medicine used for chronic Hepatitis C infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi.

Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi.

Gilead Pharma says that the recent decision by the patent office, which rejected patent for one of its molecules, does not impact its India...

Strides has entered into a licensing agreement with Gilead to manufacture and distribute latter's low-cost TAF used for HIV treatment in de...

"The main patent applications covering sofosbuvir are still pending before the Indian Patent Office," Alton said.

In what could strengthen Cipla's patent challenge against global major Gilead Science's patent application for its key HIV drug, Viread, th...

It has now emerged that Aids Healthcare Foundation (AHF), the US-based NGO that accused Cipla of over pricing anti-AIDS drug, Viraday, in I...

Domestic pharma major Cipla is opposing US-based biotech major Gilead Sciences’ patent application in India for anti-AIDS drug Viread.

Viread, the largest selling anti-HIV/AIDS drug in the United States, will be available to patients in India at a special price equivalent o...